Transplant Infectious Disease最新文献_第8页

"Reevaluating Diagnostic Criteria and Prophylactic Strategies for Aspergillus in Lung Transplant Recipients". 肺移植受者曲霉的诊断标准和预防策略的再评估。

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-07-01 Epub Date: 2025-05-12 DOI: 10.1111/tid.70052

Asad Iqbal, Aftab Ahmad, Syed Shayan Ahmad, Kashif Rasool, Syed Sardar Shah

引用次数: 0

Cytomegalovirus, the Troll of Transplantation and Cellular Therapy? 巨细胞病毒：移植和细胞治疗的巨魔？

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-06-16 DOI: 10.1111/tid.70065

Joseph Sassine, Emily A Siegrist

引用次数: 0

Diagnostic and Therapeutic Challenges of Neurocysticercosis in a Liver Transplant Recipient. 肝移植受者神经囊虫病的诊断和治疗挑战。

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-06-10 DOI: 10.1111/tid.70064

Emily Wong, Hanine El Haddad, Vivek B Beechar

引用次数: 0

Premature Discontinuation of Trimethoprim/Sulfamethoxazole Prophylaxis in Abdominal Transplant Recipients: A Deeper Dive. 腹部移植受者过早停用甲氧苄啶/磺胺甲恶唑预防：深入研究。

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-05-21 DOI: 10.1111/tid.70057

Madeline R Hudson, Tyler T Tinkham, Dan Ilges, Cassandra D Votruba, Rebecca Corey, Alyssa K McGary, Alan Gonzalez, McKenna J Beemiller, Justin M Potter, Ashkan Rastegar, Lavanya Kodali, Blanca C Lizaola-Mayo, Holenarasipur R Vikram

{"title":"Premature Discontinuation of Trimethoprim/Sulfamethoxazole Prophylaxis in Abdominal Transplant Recipients: A Deeper Dive.","authors":"Madeline R Hudson, Tyler T Tinkham, Dan Ilges, Cassandra D Votruba, Rebecca Corey, Alyssa K McGary, Alan Gonzalez, McKenna J Beemiller, Justin M Potter, Ashkan Rastegar, Lavanya Kodali, Blanca C Lizaola-Mayo, Holenarasipur R Vikram","doi":"10.1111/tid.70057","DOIUrl":"https://doi.org/10.1111/tid.70057","url":null,"abstract":"Trimethoprim/sulfamethoxazole (TMP/SMX) prophylaxis can prevent Pneumocystis jirovecii pneumonia (PJP) and other opportunistic infections (OI). We sought to assess the frequency, causative factors, and impact of early TMP/SMX discontinuation in abdominal solid organ transplant (SOT). This is a single-center, retrospective cohort study of abdominal SOT recipients at Mayo Clinic Arizona (MCA) between January 2021 and June 2023. Primary study goals were to determine the rate and reasons behind early TMP/SMX discontinuation and whether TMP/SMX prophylaxis was reinitiated. Secondary outcomes included mean duration of therapy, alternative prophylactic agent utilized, and incidence of TMP/SMX-preventable OI. A total of 930 abdominal SOT recipients were included (592 kidney, 253 liver, 85 multiorgan transplants). TMP/SMX was discontinued early in 184 (20%) patients: 77 kidney, 84 liver, 23 multiorgan. Predominant reasons for discontinuation were hyperkalemia (39%) and cytopenias (35%). Median duration of TMP/SMX prophylaxis before discontinuation was 54.5 (18.0, 93.2) days. TMP/SMX was not resumed in 62% of cases (36% kidney, 89% liver, 52% multi-organ). The predominant reason for non-resumption was alternative prophylaxis with no clear intent to rechallenge TMP/SMX (70%). Alternative prophylaxis included pentamidine (43%), none (30%), dapsone (22%), and atovaquone (5%). Of patients reinitiated, 86% (59/69) successfully remained on TMP/SMX through the prophylaxis period. One TMP-SMX-preventable OI (nocardiosis) was observed in the TMP/SMX discontinuation group. TMP/SMX is often discontinued prematurely in SOT recipients without resumption despite resolution of the offending cause. TMP/SMX prophylaxis should be maintained where possible, as alternative therapy may not offer the same broad spectrum of protection against OI.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70057"},"PeriodicalIF":2.6,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Posttransplant HBV Vaccine Compliance, Seroprotection, and Kinetics of Hepatitis B Surface Antibody in Thoracic Organ Transplant Recipients. 胸椎器官移植受者移植后乙肝疫苗依从性、血清保护和乙肝表面抗体动力学

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-05-01 Epub Date: 2025-02-24 DOI: 10.1111/tid.70015

Chia-Yu Chiu, Priya Sampathkumar, Lisa M Brumble, Holenarasipur R Vikram, Kymberly D Watt, Elena Beam

{"title":"Posttransplant HBV Vaccine Compliance, Seroprotection, and Kinetics of Hepatitis B Surface Antibody in Thoracic Organ Transplant Recipients.","authors":"Chia-Yu Chiu, Priya Sampathkumar, Lisa M Brumble, Holenarasipur R Vikram, Kymberly D Watt, Elena Beam","doi":"10.1111/tid.70015","DOIUrl":"10.1111/tid.70015","url":null,"abstract":"Introduction: Vaccination is crucial to the thoracic solid organ transplant (SOT) population to reduce vaccine-preventable infection. However, data on posttransplant hepatitis B virus (HBV) vaccination compliance and vaccine-induced seroprotection are lacking.Methods: We conducted a retrospective study of adult thoracic organ (heart and lung) transplant recipients at Mayo Clinic sites in Minnesota, Arizona, and Florida between January 2018 and August 2023. Recombivax HB was used before 2020, and Heplisav-B was preferred after 2020. Recipients with posttransplant hepatitis B surface antibody (HBsAb) < 10 IU/L were eligible for the HBV vaccine. HBV seroprotection was defined as an HBsAb ≥ 10 IU/L.Results: A total of 1116 recipients were evaluated, all of whom underwent posttransplant HBsAb testing. Of these, 751 (67%) had an HBsAb level < 10 IU/L and were eligible for posttransplant HBV vaccination. Of the eligible recipients, 117 (16%) completed the HBV vaccine series during the study period. Among these 117 recipients, 40 (34%) had their HBsAb levels rechecked after completing the vaccine series, with a seroprotection rate of 37.5% (15/40). There was no statistically significant difference in the seroprotection rates between Heplisav-B and Recombivax HB vaccines (39% [13/33] vs. 29% [2/7]; p = 0.691). In addition, HBsAb levels were lowest at week 2 but rebounded at week 4 posttransplant and pretransplant HBsAb levels of ≥100 IU/L ensured 5-year seroprotection.Conclusion: Suboptimal compliance with HBV vaccination and poor vaccine-induced seroprotection occur in thoracic organ transplant recipients, regardless of the vaccine used. These findings underscore the necessity of enhancing vaccination strategies for SOT recipients.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70015"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re: Universal Multiplex Panel Testing of Donor Lungs as a Strategy to Optimize Antibiotic Prophylaxis against Multidrug-Resistant Bacteria. 关于：供体肺的通用多重面板检测作为优化抗生素预防多重耐药细菌的策略。

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-05-01 Epub Date: 2025-03-26 DOI: 10.1111/tid.70029

Andrea Lombardi, Davide Mangioni, Giulia Renisi, Arianna Liparoti, Alessandra Bandera

引用次数: 0

Limited Risk of Microbial Contamination During Hypothermic and Normothermic Machine Perfusion of Donor Kidneys. 供肾低温和常温机器灌注过程中微生物污染的有限风险。

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-05-01 Epub Date: 2025-03-06 DOI: 10.1111/tid.70019

Julia S Slagter, Carolina A M Schurink, Ga-Lai M Chong, Marlies E J Reinders, Robert J Porte, Robert C Minnee

{"title":"Limited Risk of Microbial Contamination During Hypothermic and Normothermic Machine Perfusion of Donor Kidneys.","authors":"Julia S Slagter, Carolina A M Schurink, Ga-Lai M Chong, Marlies E J Reinders, Robert J Porte, Robert C Minnee","doi":"10.1111/tid.70019","DOIUrl":"10.1111/tid.70019","url":null,"abstract":"Background: Both hypothermic machine perfusion (HMP) and normothermic machine perfusion (NMP) are increasingly used for preservation of deceased donor kidneys. However, especially NMP can pose as a risk for microbial contamination of the kidney graft as the 37°C perfusate can act as a breeding ground for microbial contaminants.Methods: In this study, we investigated the cultures of HMP and NMP perfusates of deceased donor kidneys.Results: Between January 2021 and April 2024, a total of 99 perfusates were examined (73 HMP and 26 NMP perfusates)-. We found that contamination of HMP perfusate was common, occurring in 21 of 73 cultures (29%). Most bacteria originated from the skin. Microbial contamination during NMP was rare, occurring only in 2 of 26 cultures (8%). Microbial contamination during machine perfusion did not lead to infectious complications in the recipients.Conclusion: Machine perfusion poses a very limited risk of infection in kidney transplant recipients.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70019"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Severe Persistent BK Polyomavirus on Graft Function and Quality of Life Outcomes in Kidney Transplant Recipients. 重度持续性BK多瘤病毒对肾移植受者移植物功能和生活质量的影响

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-05-01 Epub Date: 2025-03-18 DOI: 10.1111/tid.70010

Emily M Eichenberger, Wairimu Magua, Geeta Karadkhele, Grace Zhou, Payaswini Vasanth, Christian Larsen

{"title":"Impact of Severe Persistent BK Polyomavirus on Graft Function and Quality of Life Outcomes in Kidney Transplant Recipients.","authors":"Emily M Eichenberger, Wairimu Magua, Geeta Karadkhele, Grace Zhou, Payaswini Vasanth, Christian Larsen","doi":"10.1111/tid.70010","DOIUrl":"10.1111/tid.70010","url":null,"abstract":"Background: The risk factors and outcomes associated with severe persistent BK polyomavirus (BKPyV) in kidney transplant recipients (KTR) are unknown.Methods: This is a single-center retrospective study of KTR with severe persistent BKPyV compared to (1) KTR with low/no BKPyV-DNAemia and (2) KTR with high BKPyV-DNAemia. Severe persistent BKPyV was defined as BKPyV load reaching > 6 log10 (1 000 000 copies/mL) for ≥ 90 days. Low/no BKPyV was defined as BKPyV load remaining < 3 log10 (1000 copies/mL), and high BKPyV was defined as BKPyV load ≥ 3 log10 without meeting criteria for severe persistent BKPyV.Results: Out of 2586 KTR, 22 had severe persistent BKPyV and were compared to 1843 KTR with low/no BKPyV and 721 KTR with high BKPyV. A low absolute lymphocyte count during the first month posttransplant was associated with an increased risk of severe persistent BKPyV relative to those with low/no BKPyV and high BKPyV (OR 0.91, 95%CI 0.84, 0.99). KTR with severe persistent BKPyV had significantly lower eGFR at 2 years posttransplant relative to low/no and high BKPyV groups eGFR (36 vs. 61 and 59 mL/min; p < 0.001 for both). Additionally, KTR with severe persistent BKPyV required more lab draws and incurred significantly higher total lab-associated costs relative to KTR with low/no BKPyV and high BKPyV ($7516 vs. $4631, p < 0.001; $7516 vs. $5811, p < 0.001, respectively).Conclusions: Severe persistent BKPyV is uncommon but associated with poor outcomes including impaired renal function, a higher burden of labs, and lab-associated costs. Future studies are needed to determine underlying factors that predict severe persistent BKPyV.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70010"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of Once-Weekly Dapsone for Pneumocystis jirovecii Pneumonia Prophylaxis in Kidney Transplant Recipients. 肾移植受者每周一次使用达哌酮预防肺孢子虫肺炎的安全性

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-05-01 Epub Date: 2025-02-24 DOI: 10.1111/tid.70012

Lauren Schumacher, Olivia Philippart, Abbey Carr, Catherine J Cj Sadler, Sravanthi Paluri

{"title":"Safety of Once-Weekly Dapsone for Pneumocystis jirovecii Pneumonia Prophylaxis in Kidney Transplant Recipients.","authors":"Lauren Schumacher, Olivia Philippart, Abbey Carr, Catherine J Cj Sadler, Sravanthi Paluri","doi":"10.1111/tid.70012","DOIUrl":"10.1111/tid.70012","url":null,"abstract":"Background: Sulfamethoxazole-trimethoprim (SMX-TMP) is recommended first-line for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in kidney transplant recipients. In cases of sulfa allergy or intolerance, our center utilizes dapsone 100 mg once weekly as alternative prophylaxis. As both agents have the potential to cause hematologic abnormalities, we sought to compare hematologic effect profiles of weekly dapsone versus SMX-TMP in kidney transplant recipients.Methods: This retrospective, single-center, cohort study included kidney transplant recipients who received SMX-TMP or dapsone for PJP prophylaxis. The primary endpoint was the change in hemoglobin from baseline to nadir. Secondary endpoints included hemoglobin and white blood cell (WBC) count at 1, 3, and 6 months posttransplant, time to hemoglobin nadir, neutropenia incidence, and ANC nadir. In addition, we evaluated the incidence of hospital readmission, bacteremia, and PJP.Results: A total of 509 kidney transplant recipients were included (334 SMX-TMP vs. 175 dapsone). Median decrease in hemoglobin (g/dL) from baseline to nadir was greater in the dapsone group (0 SMX-TMP vs. -0.20 dapsone; p = 0.046). Mean absolute hemoglobin count was lower in the dapsone group at all time points. There was no difference in WBC, ANC nadir, or incidence of neutropenia at any time point between groups. Greater frequencies in readmissions (30.7% vs. 55.7%; p < 0.001) and bacteremia (3.6% vs. 10.8%; p < 0.001) were observed in the dapsone arm.Conclusions: Once-weekly dapsone is associated with statistically significant decreases in hemoglobin when compared to SMX-TMP in a kidney transplant cohort, which may be clinically relevant in select patients. Dapsone use may also increase infection risk.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70012"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Titer-Proven Response Rates of Pediatric Hepatitis B-Combination Vaccines in Adult Hematopoietic Cell Transplant Recipients. 成人造血细胞移植受者儿童乙型肝炎联合疫苗滴度证实应答率的评价

IF 2.6 4区医学

Transplant Infectious Disease Pub Date : 2025-05-01 Epub Date: 2025-03-03 DOI: 10.1111/tid.70005

Charles M Gallagher, Spencer K Yingling, Aaron Cumpston, Lauren Veltri, Salah Ud Din Safi, Sijin Wen, Kelsea Seago

{"title":"Evaluation of Titer-Proven Response Rates of Pediatric Hepatitis B-Combination Vaccines in Adult Hematopoietic Cell Transplant Recipients.","authors":"Charles M Gallagher, Spencer K Yingling, Aaron Cumpston, Lauren Veltri, Salah Ud Din Safi, Sijin Wen, Kelsea Seago","doi":"10.1111/tid.70005","DOIUrl":"10.1111/tid.70005","url":null,"abstract":"Background: Patients who have undergone hematopoietic cell transplant (HCT) should be revaccinated with common childhood vaccines due to loss of immunity. It is common for transplant centers to encourage adherence by administering combination vaccines to alleviate high vaccine burden. A combination product containing pediatric doses of hepatitis B surface antigen (10 µg) is commonly utilized, although limited data are available on response post-HCT.Methods: The primary objective of this study was to determine the efficacy of a low-dose, combination hepatitis B vaccine by assessing titer-proven response rates. The secondary objective was to characterize factors that influence non-response. Post-HCT patients were included in this analysis if they received all three post-HCT doses of low-dose DTaP-HepB-IPV with a subsequently documented hepatitis B titer result. Following the successful completion of the protocol, patients were considered responders to the vaccine if they had measurable titers ≥10 mIU/mL.Results: Thirty-nine patients met inclusion criteria. A serologic response to the vaccine series was observed in 21 of the 39 patients (54%). Allogeneic HCT recipients were found to have a response rate of 76%, whereas autologous recipients were less likely to respond (response rate 36%, p = 0.02).Conclusion: An appropriate response to a low-dose, combination hepatitis B vaccine was observed in allogeneic HCT recipients. Autologous response rates are low, though this finding is consistent with prior literature.","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70005"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0